Changes in survival and time to progression in metastatic breast cancer (MBC) patients enrolled into clinical trials from 1983 to 2001.

被引：0
|
作者：
Gennari, A
Conte, P
Orlandini, C
Guarneri, V
Rosso, R
Bruzzi, P
机构：
[1] Div Med Oncol, Pisa, Italy
[2] Div Med Oncol, Modena, Italy
[3] NCI, Genoa, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
634
引用
收藏
页码：35S / 35S
页数：1
相关论文
共 50 条
  • [41] Trastuzumab (T) treatment beyond progression in metastatic breast cancer (MBC): Patterns of care in Swiss clinical practice
    Thurlimann, B.
    Rochlitz, C.
    Aebi, S. P.
    Gueth, U.
    von Moos, R.
    Mueller, A.
    Von Rohr, L. U.
    Baumann, M.
    Huober, J. B.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [42] Progression-free survival (PFS) assessment by local investigators versus blinded independent central review (BICR) in randomized clinical trials (RCTs) in metastatic breast cancer (MBC): Is it really needed?
    Jacobs, F.
    Molinelli, C.
    Agostinetto, E.
    Branco, D. Martins
    Marta, G. Nader
    Salmon, M.
    Ameye, L.
    Piccart, M.
    Lambertini, M.
    de Azambuja, E.
    ANNALS OF ONCOLOGY, 2023, 34 : S374 - S374
  • [43] Exosomal prognostic biomarkers predict metastatic progression and survival in breast cancer patients
    Serdar, Ceyhan Ceran
    Osmanlioglu, Seyma
    TURKISH JOURNAL OF BIOCHEMISTRY-TURK BIYOKIMYA DERGISI, 2023, 48 (05): : 541 - 562
  • [44] Association of Cardiovascular Risk Factors With Cardiac Events and Survival Outcomes Among Patients With Breast Cancer Enrolled in SWOG Clinical Trials
    Hershman, Dawn L.
    Till, Cathee
    Shen, Sherry
    Wright, Jason D.
    Ramsey, Scott D.
    Barlow, William E.
    Unger, Joseph M.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (26) : 2710 - +
  • [45] Estimating changes in overall survival using progression-free survival in metastatic breast and colorectal cancer
    Bowater, Russell J.
    Lilford, Philippa E.
    Lilford, Richard J.
    INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2011, 27 (03) : 207 - 214
  • [46] Neuregulin (NRG) expression modulates clinical response to herceptin in patients with metastatic breast cancer (MBC)
    de Alava, E.
    Abad, M.
    Ocana, A.
    Rodriguez, C. A.
    Montero, J. C.
    Cruz, J. J.
    Pandiella, A.
    LABORATORY INVESTIGATION, 2007, 87 : 28A - 28A
  • [47] Neuregulin (NRG) expression modulates clinical response to trastuzumab in patients with metastatic breast cancer (MBC).
    De Alava, E.
    Abad, M.
    Rodriguez, C. A.
    Montero, J. C.
    Serrano, E.
    Ocana, A.
    Torres, A.
    Ruiz, M.
    Cruz, J. J.
    Pandiella, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 557S - 557S
  • [48] Neuregulin (NRG) expression modulates clinical response to herceptin in patients with metastatic breast cancer (MBC)
    de Alava, E.
    Abad, M.
    Ocana, A.
    Rodriguez, C. A.
    Montero, J. C.
    Cruz, J. J.
    Pandiella, A.
    MODERN PATHOLOGY, 2007, 20 : 28A - 28A
  • [49] Impact on overall survival and progression free survival of local treatment in patients with metastatic breast cancer
    Maffuz-Aziz, Antonio
    Aldaneli Arredondo-Rodriguez, Bibiana
    Labastida-Almendaro, Sonia
    Alberto Tenorio-Torres, Juan
    Carbajal-Saldana, Brenda
    Rodriguez-Cuevas, Sergio
    GACETA MEXICANA DE ONCOLOGIA, 2014, 13 (02): : 106 - 111
  • [50] Factors Associated with Time to Progression and Overall Survival in Patients with De Novo Metastatic Breast Cancer: A Colombian Cohort
    Esperanza Diaz-Casas, Sandra
    Briceno-Morales, Ximena
    Juliana Puerto-Horta, Leidy
    Lehmann-Mosquera, Carlos
    Cecilia Orozco-Ospino, Martha
    Hernan Guzman-AbiSaab, Luis
    Angel-Aristizabal, Javier
    Garcia-Mora, Mauricio
    Alfonso Duarte-Torres, Carlos
    Fernando Marino-Lozano, Ivan
    Briceno-Morales, Clara
    Sanchez-Pedraza, Ricardo
    ONCOLOGIST, 2022, 27 (02): : E142 - E150
12345